Drug - Cuvposa (Glycopyrrolate Oral Solution [Shionogi Pharmaceuticals]
Patient has severe drooling caused by a neurologic disorder and cannot take glycopyrrolate as the tablet formulation. Supporting documentation must be provided at the time of request.
FDA approved indication
Cuvposa (glycopyrrolate) Oral Solution is indicated to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years.
Cuvposa reduces drooling by lowering the volume of saliva produced.
Glycopyrrolate tablets are available as 1 mg and 2 mg tablets. Costs of these tablets are $0.55 and $0.98, respectively. Cuvposa is provided as a liquid formulation of glycopyrrolate. The cost differential between tablet and liquid formulation, if based on the maximum daily dose, exceeds $1,500 per month.
Cuvposa dosing and administration
||0.02 mg/kg TID
||increments of 0.02 mg/kg every 5-7 days
||0.1 mg/kg TID not to exceed
Doses range from 1.5 to 15 mL per dose and are dependent on child’s body weight and tolerance.
Oral glycopyrrolate should be dosed at least one hour before or two hours after meals. The presence of high fat food reduces the oral bioavailability of oral glycopyrrolate if taken shortly after a meal.
MHCP Provider Call Center 651-431-2700 or 800-366-5411